News
CYBN
0.4300
+0.19%
0.0008
Weekly Report: what happened at CYBN last week (0318-0322)?
Weekly Report · 2d ago
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
Cybin Inc. Secures $150M for Psychedelic Research
TipRanks · 03/19 16:07
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
NASDAQ · 03/18 15:23
Cybin, Inc. Shines at Dallas Investor Event
TipRanks · 03/18 12:18
Weekly Report: what happened at CYBN last week (0311-0315)?
Weekly Report · 03/18 11:43
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Inc. Will participate in the Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. The company is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare. Cybin is developing next-generation psychedelic-based treatment options for mental health conditions.
Barchart · 03/18 06:30
Cybin initiates Phase 2 study for psychedelic drug DMT
Healthcare Cybin initiates Phase 2 study for psychedelic drug DMT. FDA cleared the company’s Investigational New Drug application for the DMT compound in January. Cybin expects to have topline safety and efficacy data for the drug in Q4.
Seeking Alpha · 03/15 14:24
Cybin Inc. Advances Novel Anxiety Treatment
TipRanks · 03/15 12:07
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Cybin Inc. Announced the initiation of a Phase 2 proof-of-concept study of CYB004 for the treatment of generalized anxiety disorder. The U.S. Food and Drug Administration has cleared Cybin’s Investigational New Drug application for CYb004. The company's other novel psychedelic molecule, CYB003, has been granted Breakthrough Therapy Designation by the FDA.
Barchart · 03/15 06:30
Cybin to begin Phase 3 study for psychedelic drug mid-year
Healthcare Cybin to begin Phase 3 study for psychedelic drug mid-year. Cybin plans to begin enrollment for a multinational multi-site Phase 3 program in mid-2024. The drug developer has received FDA Breakthrough Therapy Designation for CYB003 in the treatment of major depressive disorder.
Seeking Alpha · 03/14 16:52
'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Indiana lawmakers have sent a bill to the governor's desk to fund psychedelic research. The bill includes provisions to fund studies into psilocybin as a treatment for mental health conditions. The state is one of a growing number of states pursuing reform on psychedelics. Indiana lawmakers have been considering marijuana legalization.
Benzinga · 03/14 16:42
Cybin Inc. Gears Up for Global Phase 3 Depression Study
Cybin, Inc. Has announced positive feedback from the FDA regarding the Phase 2 study of their psilocybin analog, CYB003. The company is set to initiate a Phase 3 study in mid-2024. The drug is aimed at treating Major Depressive Disorder.
TipRanks · 03/14 12:07
Cybin Announces End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Cybin Inc. Announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder. The company is committed to revolutionizing mental healthcare by developing psychedelic-based treatments.
Benzinga · 03/14 11:32
Cybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating
TipRanks · 03/14 11:18
Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations
TipRanks · 03/13 15:35
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Cybin Inc. Announced the FDA has granted Breakthrough Therapy designation to its treatment for Major Depressive Disorder. The company says its psilocybin analog, CYB003, shows sustained improvement in depression symptoms at four months. If approved, it would be the first known adjunctive psychedelic-based treatment for the treatment of MDD.
Benzinga · 03/13 15:33
Cybin launches $150M oversubscribed private placement
Seeking Alpha · 03/13 12:50
Cybin Inc. Secures $150M for Depression Drug
TipRanks · 03/13 11:39
Cybin spikes after FDA breakthrough tag for psychedelic therapy
Seeking Alpha · 03/13 10:55
More
Webull provides a variety of real-time CYBN stock news. You can receive the latest news about Cybin Inc through multiple platforms. This information may help you make smarter investment decisions.
About CYBN
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.